Sanofi-aventis (Pty) Limited

Present in more than 100 countries, with around 11 000 scientists and 100 000 employees working to improve health and wellbeing, Sanofi-aventis is the leading multinational pharmaceutical company in South Africa and one of the world’s leading pharmaceutical companies. Our Global headquarters are in Paris, France. Sanofi is a diversified global healthcare leader focused on patients’ needs. As a world leader in human vaccines with a broad and balanced presence in both traditional and emerging markets, Sanofi has core strengths in the field of healthcare with its growth platforms in consumer healthcare, diabetes, innovative products and animal health. Through the acquisition of Genzyme, Sanofi has reinforced its footprint in biotechnology and rare diseases. Merial, which is The Animal Health Division of Sanofi is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of animals. Sanofi-aventis focuses its activities on 7 major therapeutic areas: Cardiovascular, Thrombosis, Oncology, Central Nervous System, Metabolic Disorders, Internal Medicine, Vaccines Sanofi-aventis provides great medicine for millions of patients. The sanofi-aventis portfolio of marketed products includes several medicines that are world leaders in their respective classes, in the areas of thrombosis, cardiovascular disease, sleep disorders, bone disease, epilepsy, diabetes and cancer. In South Africa sanofi-aventis markets a diverse product porfolio that meets South Africa's healthcare needs.